Sam Williams

Dr. Sam Williams has over 30 years of experience in the life sciences sector, spanning scientific research, company leadership and investment management. He is currently Managing Partner at IP Group plc, the FTSE 250 investor, where he oversees the group’s £400m life sciences portfolio. He is founding CEO and Chairman of Istesso Limited, a Phase 2 drug discovery company, and has served as founding investor, director and / or chairman of several leading UK private and public biotech businesses, including Diurnal Group plc, Pulmocide Limited, Genomics plc and Psioxus Limited. From 1996 to 2007, Sam worked as a biotech analyst in the City of London, most notably at Lehman Brothers where he was ranked number one European Biotechnology Research Analyst by Institutional Investor in multiple years. Sam conducted his PhD and post-doctoral research in the laboratory of Nobel Prize winner, Sir Gregory Winter, in Cambridge and has a degree in biology from Oxford.